Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Odalasvir, AL-335, and Simeprevir with Oral Contraceptives
NCT02885454Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of odalasvir and adafosbuvir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration of Drospirenone at Day 32, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time of Drospirenone at Day 32 and 4 more. Started Aug 2016; status: completed.
02
Drugs
odalasviradafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02885454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885454.